Primary chemotherapy versus primary surgery for ovarian cancer - Authors' reply

Affiliations

¹ School of Cancer Sciences, University of Birmingham, Birmingham, UK.
² Medical Research Council Clinical Trials Unit, University College London, London WC2B 6NH, UK. Electronic address: m.nankivell@ucl.ac.uk.

Comment

Sean Kehoe et al. Lancet. 2015.

. 2015 Nov 28;386(10009):2143.

doi: 10.1016/S0140-6736(15)01052-1.

¹ School of Cancer Sciences, University of Birmingham, Birmingham, UK.
² Medical Research Council Clinical Trials Unit, University College London, London WC2B 6NH, UK. Electronic address: m.nankivell@ucl.ac.uk.

No abstract available

Comment on

Primary chemotherapy versus primary surgery for newly diagnosed advanced ovarian cancer (CHORUS): an open-label, randomised, controlled, non-inferiority trial.
Kehoe S, Hook J, Nankivell M, Jayson GC, Kitchener H, Lopes T, Luesley D, Perren T, Bannoo S, Mascarenhas M, Dobbs S, Essapen S, Twigg J, Herod J, McCluggage G, Parmar M, Swart AM. Kehoe S, et al. Lancet. 2015 Jul 18;386(9990):249-57. doi: 10.1016/S0140-6736(14)62223-6. Epub 2015 May 19. Lancet. 2015. PMID: 26002111 Clinical Trial.
Primary chemotherapy versus primary surgery for ovarian cancer.
Gasparri ML, Panici PB, Papadia A. Gasparri ML, et al. Lancet. 2015 Nov 28;386(10009):2142-3. doi: 10.1016/S0140-6736(15)01051-X. Lancet. 2015. PMID: 26638961 No abstract available.
Primary chemotherapy versus primary surgery for ovarian cancer.
Scaletta G, Plotti F, Aloisi A, Angioli R. Scaletta G, et al. Lancet. 2015 Nov 28;386(10009):2142. doi: 10.1016/S0140-6736(15)01050-8. Lancet. 2015. PMID: 26638962 No abstract available.